146552-71-8

Basic information

• Product Name: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)
• Synonyms: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI);(S)-tert-butyl 1-aminopropan-2-ylcarbamate;tert-butyl N-[(2S)-1-aMinopropan-2-yl]carbaMate;N-((S)-2-Amino-1-methylethyl)carbamic acid tert-butyl ester;tert-Butyl ((S)-1-aminopropan-2-yl)carbamate;(S)-2-N-Boc-propane-1,2-diaMine;CarbaMic acid, N-[(1S)-2-aMino-1-Methylethyl]-, 1,1-diMethylethyl ester;Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester
• CAS NO: 146552-71-8
• Molecular Formula: C₈H₁₈N₂O₂
• Molecular Weight: 174.24072
• Product Categories: N-BOC
• Mol File: 146552-71-8.mol

Chemical Properties

• Boiling Point: 264℃
• Flash Point: 113℃
• Appearance: /
• Density: 0.984
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.19±0.46(Predicted)
• CAS DataBase Reference: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(146552-71-8)
• EPA Substance Registry System: Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI)(146552-71-8)

Safety Data

• Hazardous Substances Data: 146552-71-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is used as a reagent in organic synthesis for various chemical reactions, facilitating the formation of desired products and improving the efficiency of the synthesis process.
Used in Peptide Synthesis as a Protecting Group for Amines:
In the pharmaceutical and biotechnology industries, Carbamic acid, [(1S)-2-amino-1-methylethyl]-, 1,1-dimethylethyl ester (9CI) is utilized as a protecting group for amines during peptide synthesis. This protects the amine functionality from unwanted side reactions, allowing for the selective formation of peptide bonds and the synthesis of complex peptide structures with greater control and precision.

Upstream product

• 146610-69-7 1-azido-(S)-2-(N-tert-butoxycarbonyl)aminopropane 
• 79069-13-9 (S)-2-t-butoxycarbonylaminopropan-1-ol 
• 126301-16-4 (2S)-2-[(tert-butoxycarbonyl)amino]propyl methanesulfonate 
• 15967-72-3 (S)-1,2-diaminopropane 
• 78981-25-6 tert-butyl (1S)-2-amino-1-methyl-2-oxoethylcarbamate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 109208-68-6 Boc-Ala-O-COO-isoBu 
• 15761-38-3 L-N-Boc-Ala 
• 28875-17-4 (S)-N-(tert-butoxycarbonyl)alanine methyl ester 

Downstream Products

• 19777-66-3 (S)-propane-1,2-diamine dihydrochloride 
• 824399-47-5 t-butyl (S)-2-{[3-cyano-2-(3,5-dimethoxyphenylamino)-5-methylpyrazolo[1,5-a]pyrimidin-7-yl]amino}-1-methylethylcarbamate 
• 735273-02-6 (S,S)-{2-[2-tert-butoxycarbonylamino-3-(4-nitro-phenyl)-propionylamino]-1-methyl-ethyl}-carbamic acid tert-butyl ester 
• 1217317-62-8 (S)-benzyl tert-butyl propane-1,2-diyldicarbamate 
• 1188301-70-3 (S)-tert-butyl 1-(4-(4-bromo-2-(4-trifluoromethyl)phenyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 294648-89-8 C₂₉H₃₇N₇O₂ 
• 1301178-01-7 C₂₉H₃₉BrN₄O₃ 
• 1353576-40-5 (S)-tert-butyl 1-(4-(2-tert-butyl-4-(2-chloro-5-fluoro-3-(methylsulfonamido)phenyl)thiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353576-45-0 (S)-tert-butyl 1-(4-(4-(2-chloro-5-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353576-51-8 (S)-tert-butyl-1-(4-(4-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropyloxazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate 
• 1353576-48-3 (S)-methyl 1-(4-(4-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-2-cyclopropylthiazol-5-yl)pyrimidin-2-ylamino)propan-2-ylcarbamate trifluoroacetate 
• 882419-75-2 tert-butyl N-[2-(benzylamino)-1-methyl-ethyl]carbamate 

Relevant articles and documents

NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF

An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.

METALLO-BETA-LACTAMASE INHIBITORS

The present invention relates to compounds of formula I that are metallo-β-lactamase inhibitors, the synthesis of such compounds, and the use of such compounds for use with β-lactam antibiotics for overcoming resistance.

Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering

The propensity for cancer cells to accumulate additional centrosomes relative to normal cells could be exploited for therapeutic benefit in oncology. Following literature reports that suggested TNKS1 (tankyrase 1) and PARP16 may be involved with spindle s

Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists

Abstract The optimization efforts that led to a novel series of methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones that are potent rat and human P2X7 antagonists are described. These efforts resulted in the discovery of co

PEPTIDE-OLIGOUREA CHIMERIC COMPOUNDS AND METHODS OF THEIR USE

The present description provides compositions and methods for producing therapeutic oligomeric compounds. In another aspect the description provides methods for administering the oligomeric compounds for the treatment and prevention of disease in a mammal. In particular, the invention relates to medicaments comprising various novel oligomeric compounds and pharmaceutically acceptable salts thereof. The compounds of the invention may optionally be administered with at least one of a pharmaceutically acceptable excipient, additional pharmacologically active agent or a combination thereof.

CARBAZOLE-CONTAINING AMIDES, CARBAMATES, AND UREAS AS CRYPTOCHROME MODULATORS

The subject matter herein is directed to carbazole-containing amide, carbamate, and urea derivatives and pharmaceutically acceptable salts or hydrates thereof of structural formula I wherein the variable R1, R2, R3, R4, R5, R6, R7, A, D, E, G, J, L, M, Q, a, and b are accordingly described. Also provided are pharmaceutical compositions containing the compounds of formula I to treat a Cry-mediated disease or disorder, such as diabetes, complications associated with diabetes, Cushing's syndrome, NASH, NAFLD, asthma, and COPD.

Sequential enantiodivergent organocatalysis: Reversibility in enantioswitching controlled by a conformationally flexible guanidine/bisthiourea organocatalyst

Here we describe our studies on solvent-dependent enantiodivergent Mannich-type reactions utilizing conformationally flexible guanidine/bisthiourea organocatalyst (S,S)-1. Our mechanistic investigations revealed that the stereo-determining steps in both t

Novel Heterocyclic Compounds and Uses Thereof

New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines

We report the synthesis and biological evaluation of a series of novel α-branched pyrazinoyl quaternary amines for their ability to block ion transport via the epithelial sodium channel (ENaC) in human bronchial epithelial cells (HBECs). Compound 12g has an IC50 of 30 nM and is highly efficacious in the Guinea-pig tracheal potential difference (TPD) model of ENaC blockade with an ED50 of 1 μg kg-1 at 1 h. In addition the SAR results demonstrate for the first time the chiral nature of the binding site of human ENaC. As such, pyrazinoyl quaternary amines represent a promising new class of ENaC blockers for the treatment of cystic fibrosis that are structurally distinct from the pyrazinoyl guanidine chemotype found in prototypical ENaC blockers such as amiloride.

Synthesis of imidacloprid derivatives with a chiral alkylated imidazolidine ring and evaluation of their insecticidal activity and affinity to the nicotinic acetylcholine receptor

A series of imidacloprid (IMI) derivatives with an alkylated imidazolidine ring were asymmetrically synthesized to evaluate their insecticidal activity against adult female housefly, Musca domestica, and affinity to the nicotinic acetylcholine receptor of the flies. The bulkier the alkyl group, the lower was the receptor affinity, but the derivatives methylated and ethylated at the R-5-position of the imidazolidine ring were equipotent to the unsubstituted compound. Quantitative structure-activity relationship (QSAR) analysis of the receptor affinity demonstrated that the introduction of a substituent into the imidazolidine ring was fundamentally disadvantageous, but the introduction of a substituent at the R-5-position was permissible in the case of its small size. The binding model of the synthesized derivatives with the receptor supported the QSAR analysis, indicating the existence of space for a short alkyl group around the R-5-position in the ligand-binding site. In addition, positive correlation was observed between the insecticidal activity and receptor affinity, suggesting that the receptor affinity was the primary factor in influencing the insecticidal activity even if the imidazolidine ring was modified.